INTRODUCTION:

An antifungal agent is a drug that selectively eliminates fungal pathogens from a host with minimal toxicity to the host. The development of antifungal agents has lagged behind that of antibacterial agents. This is a predictable consequence of the cellular structure of the organisms involved. Bacteria are prokaryotic and hence offer numerous structural and metabolic targets that differ from those of the human host.

Fungi, in contrast, are eukaryotes, and consequently most agents toxic to fungi are also toxic to the host. Furthermore, because fungi generally grow slowly and often in multicellular forms, they are more difficult to quantify than bacteria. This difficulty complicates experiments designed to evaluate the in vitro or in vivo properties of a potential antifungal agent. Despite these limitations, numerous advances have been made in developing new antifungal agents and in understanding the existing ones. This chapter summarizes the more common antifungal agents. Three groups of drugs are emphasized: the polyenes, the azoles, and one antimetabolite. Table 76-1 summarizes the most important antifungal agents and their most common uses. An antifungal medication, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete’s foot, ringworm, candidiasis, serious systemic infections such as Cryptococci meningitis, and others

Antifungal agents Mechanisms of action:

Clinical needs for novel antifungal agents have altered steadily with the rise and fall of AIDS-related mycoses, And the change in spectrum of fatal disseminated fungal Infections that has accompanied changes in therapeutic Immunosuppressive therapies. The search for new Molecular targets for antifungals has generated con- Siderable research using modern genomic approaches, So far without generating new agents for clinical use. Meanwhile, six new antifungal agents have just Reached, or are approaching, the clinic. Three are new Triazoles, with extremely broad antifungal spectra, and Three are echinocandins, which inhibit synthesis of fun- Gal cell wall polysaccharides – a new mode of action. In Addition, the sordarins represent a novel class of agents That inhibit fungal protein synthesis. This review Describes the targets and mechanisms of action of all Classes of antifungal agents in clinical use or with Clinical potential.^1,2,3,4,5 The earliest inhibitory agent specific to fungal species was griseofulvin. The precise mechanism of action of this compound is still unknown but the favoured explanation is that it interferes with microtubule assem- bly. The selective toxicity of griseofulvin for fungi is only moderate (liver toxicity is recognised as an occasional hazard) and its spectrum of action is restricted mainly to the dermatophyte fungi – causes of ringworm and athlete’s foot. However, other types of compound are known to interfere with microtubule assembly and function in pathogenic fungi, such as C. Informants.^6,7,8,9, Effects on microtubules explained the antifungal activity of early compounds, such as benzimidazole. However, unlike the situation in fungicide research against plant pathogens, relatively little research attention seems to have been paid in recent years to microtubules as possible antifungal targets for clinical use.^10,11,13

Types of antifungal:-

There are two types of antifungals: local and systemic. Local antifungals are usually administered topically or vaginally, depending on the condition being treated. Systemic antifungals are administered orally or intravenously. Of the clinically employed azole antifungals, only a handful are used systemically.These include ketoconazole, itraconazole, fluconazole, fosfluconazole, voriconazole, posaconazole, and isavuconazole. Examples of non-azole systemic antifungals include griseofulvin and terbinafine.^15,16

Class of Antifungal:

Polyenes

A polyene is a molecule with multiple conjugated double bonds. A polyene antifungal is a macrocyclic polyene with a heavily hydroxylated region on the ring opposite the conjugated system. This makes polyene antifungals amphiphilic. The polyene antimycotics bind with sterols in the fungal cell membrane, principally ergosterol. This changes the transition temperature (Tg) of the cell membrane, thereby placing the membrane in a less fluid, more crystalline state. (In ordinary circumstances membrane sterols increase the packing of the phospholipid bilayer making the plasma membrane more dense.) ^17,18 As a result, the cell’s contents including monovalent ions (K+, Na+, H+, and Cl−) and small organic molecules leak, which is regarded one of the primary ways a cell dies. Animal cells contain cholesterol instead of ergosterol and so they are much less susceptible. However, at therapeutic doses, some amphotericin B may bind to animal membrane cholesterol, increasing the risk of human toxicity. Amphotericin B is nephrotoxic when given intravenously. As a polyene’s hydrophobic chain is shortened, its sterol binding activity is increased. Therefore, further reduction of the hydrophobic chain may result in it binding to cholesterol, making it toxic to animals.¹⁹

Amphotericin B:- various formulations are available to treat aspergillosis, blastomycosis, cryptococcosis, histoplasmosis (off-label), mucosal or invasive Candida infections, and coccidioidomycosis

Candicidin

Filipin – 35 carbons, binds to cholesterol (toxic)

Hamycin

Natamycin – 33 carbons, binds well to ergosterol

Nystatin:- Candida infections of the skin and mouth

Rimocidin

Azoles

Azoles inhibit conversion of lanosterol to ergosterol by inhibition of lanosterol 14α-demethylase.⁴

· Imidazole

· Bifonazole

· Butoconazole

· Clotrimazole

· Econazole

· Fenticonazole

· Isoconazole

· Ketoconazole

· Luliconazole

· Miconazole

· Omoconazole

· Oxiconazole

· Sertaconazole

· Siliconizes

· Tioconazole

Triazoles:

· Albaconazole

· Efinaconazole

· Epoxiconazole

· Fluconazole

· Isavuconazole

· Itraconazole

· Posaconazole

· Propiconazole

· Ravuconazole

· Terconazole

· Voriconazole

Thiazoles

· Abafungin

Allylamines

Allylaminesinhibit squalene epoxidase, another enzyme required for ergosterol synthesis. Examples include butenafine, naftifine, and terbinafine. Like the azole antifungals, allylamines interfere with an enzyme that’s involved in the creation of the fungal cell membrane. One example of an allylamine is terbinafine, which is often used to treat fungal infections of the skin. ^20,22

Echinocandins

Echinocandins inhibit the creation of glucan in the fungal cell wall by inhibiting 1,3-Beta-glucan synthase: Echinocandins are a newer type of antifungal drug. They inhibit an enzyme that’s involved in the making of the fungal cell wall.

• Anidulafungin: mucosal and invasive Candida infections

• Caspofungin: mucosal and invasive Candida infections, aspergillosis

• Micafungin: mucosal and invasive Candida infections

Echinocandins are administered intravenously, particularly for the treatment of resistant Candida species.

Triterpenoids

• Ibrexafungerp

Pharmacology of Systemic Antifungal Agents:

Traditionally, many invasive fungal infections were associated with a poor prognosis, because effective ther- Apeutic options were limited. The recent development of new antifungal agents has significantly contributed To the successful treatment of fungal diseases. These drugs offer novel mechanisms of action and expanded Spectrums of activity over traditional treatment options. However, with these new agents comes the need for Increased awareness of the potential interactions and toxicities associated with these drugs. Therefore, an Understanding of the pharmacokinetic and pharmacodynamics properties of the classes of antifungal compounds Is vital for the effective management of invasive fungal infections. This review provides a summary of the Pharmacologic principles involved in treatment of fungal disease.[21][22][23]

Antifungal medicines

Infections antifungals can treat

Fungal infections commonly treated with antifungals include:

• Ringworm

• Athlete’s foot

• Fungal nail infection

• Vaginal thrush

• Some types of severe dandruff

• Some fungal infections can grow inside the body and need to be treated in hospital.

• Examples include:

• Aspergillosis, which affects the lungs

• Fungal meningitis, which affects the brain

You’re more at risk of getting one of these more serious fungal infections if you have a weakened immune system – for example, if you’re taking medicines to suppress your immune system.

Types of antifungal medicines:

You can get antifungal medicines as:

• A cream, gel, ointment or spray

• A capsule, tablet or liquid

• An injection

• A pessary: a small and soft tablet you put inside the vagina

Common names for antifungal medicines include:

• Clotrimazole

• Econazole

• Miconazole

• Terbinafine

• Fluconazole

• Ketoconazole

• Amphotericin

Antifungal medicines for children:

Some antifungal medicines can be used to treat children and babies – for example, miconazole oral gel can be used for oral thrush in babies.But different doses are usually needed for children of different ages. Speak to a pharmacist or GP for more advice.^24,25

Side effects of antifungal medicines:

Antifungal medicines may cause side effects. These are usually mild and do not last long. They can include:

• Itching or burning

• Redness

• Feeling sick

• Tummy (abdominal) pain

• Diarrhoea

• A rash

Occasionally, antifungal medicines may cause a more severe reaction, such as:

• An allergic reaction – your face, neck or tongue may swell and you may have difficulty breathing

• A severe skin reaction – such as peeling or blistering skin

• Liver damage (very rarely) – you may have loss of appetite, vomiting, nausea, jaundice, dark pee or pale poo, tiredness or weakness

Stop using the medicine if you have these severe side effects, and see a GP or pharmacist to find an alternative.^26,27,28

CONCLUSION:

Antifungal medicines are used to treat fungal infections, which most commonly affect your skin, hair and nails. You can get some antifungal medicines from a pharmacy without needing a GP prescription. Antifungal medicines work by either: Killing the fungus Preventing the fungus from growing. And there are so many use of antifungal agents in the formation of medication, and antifungal have so many type for each antifungal disease give proper treatment. Amphotericin B is the mainstay antifungal agent for treatment of life -threatening mycoses and for most other mycoses, with the possible exception of the dermatophytes’ so all particular type particular information about the antifungal are mentioned in this review paper.

REFERENCE:

1. Develoux, M. (2001) Griseofulvin. Ann. Dermatol. Venere´ol. 128,1317–1325

2. Woyke, T. Et al. (2002) Effect of auristatin PHE on microtubuleIntegrity and nuclear localization in Cryptococcus neoformans. AntimicrobAntimicrob. Agents Chemother. 46, 3802–3808

3. Pfaller, M.A. et al. (2002) In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary Resistance using national committee for clinical laboratory standards Susceptibility testing methods. Antimicrob. Agents Chemother. 46,3518–3521

4. Brajtburg, J.K. et al. (1974) The molecular basis for the selective Toxicity of amphotericin B for yeast and filipin for animal oils. Antimicrob. Agents Chemother. 5, 377–382

5. Dupont, B. (2002) Overview of the lipid formulations of amphotericin B. J. Antimicrob. Chemother. 49, 31–36

6. Zarif, L. Et al. (2000) Cochleates: new lipid-based drug delivery system. JJ. Liposome Res. 10, 523–538

7. Falk, R. Et al. (1999) A novel injectable water-soluble amphotericin B-arabinogalactan conjugate. Antimicrob. Agents Chemother. 43,1975–1981

8. Anonymous (2001) Liposomal nystatin – Nyotranw Antifungal. Drugs Future 26, 810

9. Vanden Bossche, H. Et al. (1995) P450 inhibitors of use in medical Treatment: focus on mechanisms of action. Pharmacol. Ther. 67,79–100

10. Kauffman CA. New antifungal agents. Semin Respir Crit Care Med 2004;25: 233-239.

11. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azoleAntifungal agents. Clin Microbiol Rev 1999; 12: 40-79.

12. Walsh TJ, Groll A, Hiemenez J, et al. Infections due to emerging and Uncommon medically important fungal pathogens. Clin Microbial Infect2004; 10 Suppl 1: 48-66.

13. Pfaller MA, Diekma DJ. Rare and emerging opportunistic fungal patho-Gens: concern for resistance beyond Candida albicans and AspergillusFumigatus. J Clin Microbiol 2004; 42: 4419-4431.

14. Hajjeh RA, Sofair AN, Harrison LH, et al. Incidence of blood streamInfection due to Candida species and in vitro susceptibilities of isolatesCollected from 1998 to 2000 in a population-based active surveillance Program. J Clin Microbiol 2004; 42: 1519-1527.

15. Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould Infections in haematopoietic stem cell transplant recipients. Clin InfectDis 2002; 34: 909-917.

16. Lin S, Schranz J, Teutsch S. Aspergillosis case-fatality rate: systemicReview of the literature. Clin Infect Dis 2001; 32: 358-366.

17. Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality ofCandidaemia, revisited. Clin Infect Dis 2003; 37: 1172-1177.

18. Ullmann AJ, Cornerly OA. Antifungal prophylaxis for invasive mycoses inHigh risk patients. Curr Opin Infect Dis 2006; 19: 571-576.

19. Bow EJ, Laverdière M, Lussier N, et al. Antifungal prophylaxis for severely Neutropenic chemotherapy recipients. A meta-analysis of randomized-Controlled clinical trials. Cancer 2002; 94: 3230-3246.

20. Cornerly OA, Ullmann AJ, Karthaus M. Evidence-based assessment of Primary antifungal prophylaxis in patients with hematological malignan-Cies. Blood 2003; 101: 3365-3372.

21. Georgopapadakou NH, Walsh TJ. Antifungal agents: chemotherapeutic Targets and immunologic strategies. Antimicrob Agents Chemother 1996; 40: 279-291.

22. Boucher HW, Groll AH, Chiou C, Walsh TJ. Newer systemic antifungal Agents. Drugs 2004; 64: 1997-2020.

23. Torres HA, Hachem RY, Chemaly RF, et al. Posaconazole: a broad-Spectrum triazole antifungal. Lancet Infect Dis 2005; 5: 775-785.

24. Marr KA, Hachem R, Papanicolaou G, et al. Retrospective study of The hepatic safety profile of patients concomitantly treated with cas Pofungin and cyclosporin A. Transpl Infect Dis

25. Wang E-J, Lew K, Casciano CN, Clement RP, Johnson WW. Inter-

26. Action of common azole antifungals with P glycoprotein. Antimicrob

27. macrodilution susceptibility test results for non-AIDS patients wWingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta

28. A randomized, double-blind comparative trial evaluating the safety Of liposomal amphotericin B versus amphotericin B lipid complex in The empirical treatment of febrile neutropenia. L Amph/ABLC Col-Laborative Study Group. Clin Infect Dis 2000; 31:1155–63.

29. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Klei- Nermans D. Pharmacokinetics and safety of voriconazole following Intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002; 46:2546–53.

Received on 25.09.2021 Modified on 26.11.2021

Res. J. Pharma. Dosage Forms and Tech.2022; 14(1):29-32.

DOI: 10.52711/0975-4377.2022.00005